LRRK2 and Platelet storage pool disease: It has been suggested that LRRK2-and GCase-targeted therapies may benefit sporadic PD (sPD) also on the basis of an increase in LRRK2 kinase activity13 and a deficiency in GCase14 in brains of sPD cases, though the former data have not been replicated broadly6,15.